期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
基于药机对应探析仲景治疗失眠的基本方法 被引量:5
1
作者 郭仲凯 周永学 李翠娟 《陕西中医》 CAS 2021年第11期1594-1597,共4页
本文从张仲景治疗失眠代表方剂的主要药味入手,以药测证,以证求机,以机溯理,总结归纳仲景治疗失眠的基本方法。主要包括以黄连为代表药味的清心泻火法;以桂枝为代表药味的温阳安神法;以酸枣仁为代表药味的养血安魂法;以百合为代表药味... 本文从张仲景治疗失眠代表方剂的主要药味入手,以药测证,以证求机,以机溯理,总结归纳仲景治疗失眠的基本方法。主要包括以黄连为代表药味的清心泻火法;以桂枝为代表药味的温阳安神法;以酸枣仁为代表药味的养血安魂法;以百合为代表药味的滋补津液法;以半夏为代表药味的消痰化饮法;以龙骨、牡蛎为代表药味的补水制火法;以石膏为代表药味的清金散热法;以枳实为代表药味的疏肝理气法;以柴胡为代表药味的和解少阳法;以猪苓、茯苓、泽泻为代表药味的利水泄热法;以芍药为代表药味的活血祛瘀法和以大黄为代表药味的通腑降浊法。这些方法医理深刻、病机清晰、指向精准,既可以为现代临床辨治失眠疾病提供路径选择,也能在理论上有助于进一步认识失眠成因和治疗机理。 展开更多
关键词 失眠 药机对应 张仲景 清心泻火 温阳安神
下载PDF
Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis 被引量:6
2
作者 Qi-Min Su Xiao-Guang Ye 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第43期6290-6301,共12页
AIM:To compare the effects of telbivudine (LDT) and entecavir (ETV) in treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B by meta-analysis. METHODS:We conducted a literature search using PubMed, M... AIM:To compare the effects of telbivudine (LDT) and entecavir (ETV) in treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B by meta-analysis. METHODS:We conducted a literature search using PubMed, MEDLINE, EMBASE, the China National Knowledge Infrastructure, the VIP database, the Wanfang database and the Cochrane Controlled Trial Register for all relevant articles published before April 1, 2012. Randomized controlled trials (RCTs) comparing LDT with ETV for treatment of HBeAg-positive chronic hepatitis B were included. The data was analyzed with Review Manager Software 5.0. We used relative risk (RR) as an effect measure, and reported its 95% CI. Meta-analysis was performed using either a fixedeffect or random-effect model, based on the absence or presence of significant heterogeneity. Two reviewers assessed the risk of bias and extracted data indepen- dently and in duplicate. The analysis was executed using the main outcome parameters including hepatitis B virus (HBV) DNA undetectability, alanine aminotransferase (ALT) normalization, HBeAg loss, HBeAg seroconversion, drug-resistance, and adverse reactions. Meta-analysis of the included trials and subgroup analyses were conducted to examine the association between pre-specified characteristics with the therapeutic effects of the two agents. RESULTS:Thirteen eligible trials (3925 patients in total) were included and evaluated for methodological quality and heterogeneity. In various treatment durations of 4 wk, 8 wk, 12 wk, 24 wk, 36 wk, 48 wk, 52 wk, 60 wk and 72 wk, the rates of HBV DNA undetectability and ALT normalization in the two groups were similar, without statistical significance. At 4 wk and 8 wk of the treatment, no statistical differences were found in the rate of HBeAg loss between the two groups, while the rate in the LDT group was higher than in the ETV group at 12 wk, 24 wk, 48 wk and 52 wk, respectively (RR 2.28, 95% CI 1.16, 7.03, P = 0.02; RR 1.45, 95% CI 1.16, 1.82, P = 0.001; RR 1.45, 95% CI 1.11, 1.89, P = 0.006; and RR 1.86, 95% CI 1.04, 3.32, P = 0.04). At 4 wk, 8 wk, 60 wk and 72 wk of the treatment, there were no significant differences in the rate of HBeAg seroconversion between the two groups, while at 12 wk, 24 wk, 48 wk and 52 wk, the rate in the LDT group was higher than in the ETV group (RR 2.10, 95% CI 1.36, 3.24, P = 0.0008; RR 1.71, 95% CI 1.29, 2.28, P = 0.0002; RR 1.86, 95% CI 1.36, 2.54, P < 0.0001; and RR 1.87, 95% CI 1.21, 2.90, P = 0.005). The rate of drug-resistance was higher in the LDT group than in the ETV group (RR 3.76, 95% CI 1.28, 11.01, P = 0.02). In addition, no severe adverse drug reactions were observed in the two groups. And the rate of increased creatine kinase in the LDT group was higher than in the ETV group (RR 5.58, 95% CI 2.22, 13.98, P = 0.0002). CONCLUSION:LDT and ETV have similar virological and biomedical responses, and both are safe and well tolerated. However, LDT has better serological response and higher drug-resistance. 展开更多
关键词 Telbivudine Entecavir Hepatitis B e antigen-positive chronic hepatitis B Randomized controlled trials Meta-analysis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部